Position in EXEL
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$360,194
-$177,089 QoQ
Shares Held
6,620
-47.2% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.22%
of 13F equity value
Holder Rank
#493
of 755 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Essential Partners LLC holds $3,293,791 across 185 Biotechnology names. EXEL ranks #3 (10.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
6,122 | $693,989 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
713 | $444,584 | |
| 3 | EXEL |
Exelixis, Inc.
This page
|
6,620 | $360,194 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
378 | $187,763 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
3,131 | $179,155 | |
| 6 | CORT |
Corcept Therapeutics Inc
|
1,384 | $120,338 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
328 | $79,038 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
252 | $75,859 |
All Filings in EXEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $360,194 | 6,620 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $537,283 | 12,527 | Shares | Sole | 2026-05-21 | |
| 2025-12-31 | $1,067,085 | 24,346 | Shares | Sole | 2026-05-21 | |
| 2025-09-30 | $730,349 | 17,684 | Shares | Sole | 2026-05-21 | |
| 2025-06-30 | $710,525 | 16,119 | Shares | Sole | 2026-05-21 | |
| No filing history on record for this holder in this stock. | ||||||